Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

PG&E Q2 EPS $0.25 Misses $0.28 Estimate

-Reuters
byMichael Horton
July 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

-Reuters

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Immuron Announced Request for AU$5.4M (US$4M) Additional Funding from the U.S. Department of Defense for Travelan Considered to be Eligible for Award

By Charles Gross
Today, 8:07 AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium' (MTEC).

IMRN